193 related articles for article (PubMed ID: 29765225)
1. Increased risk of adverse drug events secondary to bevacizumab treatment in patients with advanced or metastatic breast cancer: a meta-analysis of randomized controlled trials.
Shin S; Noh Y
Ther Clin Risk Manag; 2018; 14():833-847. PubMed ID: 29765225
[TBL] [Abstract][Full Text] [Related]
2. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
Wagner AD; Thomssen C; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.
Chuai Y; Rizzuto I; Zhang X; Li Y; Dai G; Otter SJ; Bharathan R; Stewart A; Wang A
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013348. PubMed ID: 33661538
[TBL] [Abstract][Full Text] [Related]
4. Adverse events of bevacizumab for triple negative breast cancer and HER-2 negative metastatic breast cancer: A meta-analysis.
Xun X; Ai J; Feng F; Hong P; Rai S; Liu R; Zhang B; Zhou Y; Hu H
Front Pharmacol; 2023; 14():1108772. PubMed ID: 36794276
[No Abstract] [Full Text] [Related]
5. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of bevacizumab in elderly patients with advanced colorectal cancer: A meta-analysis.
Chen X; Chen Y; Cai X; Zhang D; Fan L; Qiu H; Zhang B; Guo G
J Cancer Res Ther; 2017; 13(5):869-877. PubMed ID: 29237919
[TBL] [Abstract][Full Text] [Related]
7. Risk of antiangiogenic adverse events in metastatic colorectal cancer patients receiving aflibercept in combination with chemotherapy: A meta-analysis.
Ge P; Han C; Reyila A; Liu D; Hong W; Liu J; Zhang J; Han X; Li X; Huang M; Fan S; Kaierdebieke A; Wu X; Huang X; Guo W; Liu S; Bian Y
Medicine (Baltimore); 2023 Sep; 102(35):e34793. PubMed ID: 37657052
[TBL] [Abstract][Full Text] [Related]
8. Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials.
Hang XF; Xu WS; Wang JX; Wang L; Xin HG; Zhang RQ; Ni W
Eur J Clin Pharmacol; 2011 Jun; 67(6):613-23. PubMed ID: 21243343
[TBL] [Abstract][Full Text] [Related]
9. Incidence and risk of hypertension with bevacizumab in non-small-cell lung cancer patients: a meta-analysis of randomized controlled trials.
Chen J; Lu Y; Zheng Y
Drug Des Devel Ther; 2015; 9():4751-60. PubMed ID: 26316712
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
11. Risk of adverse events with bevacizumab addition to therapy in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.
Lai XX; Xu RA; Yu-Ping L; Yang H
Onco Targets Ther; 2016; 9():2421-8. PubMed ID: 27143937
[TBL] [Abstract][Full Text] [Related]
12. Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis.
An MM; Zou Z; Shen H; Liu P; Chen ML; Cao YB; Jiang YY
Eur J Clin Pharmacol; 2010 Aug; 66(8):813-21. PubMed ID: 20401474
[TBL] [Abstract][Full Text] [Related]
13. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials.
Ranpura V; Hapani S; Chuang J; Wu S
Acta Oncol; 2010 Apr; 49(3):287-97. PubMed ID: 20156114
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of bevacizumab in patients with malignant melanoma: a systematic review and PRISMA-compliant meta-analysis of randomized controlled trials and non-comparative clinical studies.
Han X; Ge P; Liu S; Yang D; Zhang J; Wang X; Liang W
Front Pharmacol; 2023; 14():1163805. PubMed ID: 37521468
[No Abstract] [Full Text] [Related]
15. Vascular endothelial growth factor receptor tyrosine kinase inhibitors versus bevacizumab in metastatic colorectal cancer: A systematic review and meta-analysis.
Lin Z; Yang Y; Huang Y; Liang J; Lu F; Lao X
Mol Clin Oncol; 2015 Jul; 3(4):959-967. PubMed ID: 26171215
[TBL] [Abstract][Full Text] [Related]
16. Addition of bevacizumab to chemotherapy in patients with ovarian cancer: a systematic review and meta-analysis of randomized trials.
Li J; Zhou L; Chen X; Ba Y
Clin Transl Oncol; 2015 Sep; 17(9):673-83. PubMed ID: 25990506
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis.
Zhao T; Wang X; Xu T; Xu X; Liu Z
Oncotarget; 2017 Aug; 8(31):51492-51506. PubMed ID: 28881662
[TBL] [Abstract][Full Text] [Related]
18. Cochrane Review: Osmotic and stimulant laxatives for the management of childhood constipation (Review).
Gordon M; Naidoo K; Akobeng AK; Thomas AG
Evid Based Child Health; 2013 Jan; 8(1):57-109. PubMed ID: 23878124
[TBL] [Abstract][Full Text] [Related]
19. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis.
Ranpura V; Pulipati B; Chu D; Zhu X; Wu S
Am J Hypertens; 2010 May; 23(5):460-8. PubMed ID: 20186127
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
